Researchers atAirlangga University (Unair) and the State Intelligence Agency (BIN) released on June 12what appeared to be an encouraging statement:the discovery of five combination drug therapies and two stem cell therapies for treating COVID-19.
The acute respiratory disease caused by the SARS-CoV-2 virus has claimed at least 2,000 lives in Indonesia to date.
The joint statementattributed to Unair andBIN also said that themedicines were ready for distributionin treating COVID-19 patients.
Drug combinations
The five combination therapiesfor COVID-19 are: lopinavir/ritonavir with azithromycin, lopinavir/ritonavir with doxycycline, lopinavir/ritonavir with clarithromycin, hydroxychloroquine with azithromycin, and hydroxychloroquine with doxycycline.
In addition, the statementclaimed that the researchers had identified two types of isolated stemcells that inhibitedSARS-CoV-2 activity:hematopoietic stem cells (HSCs) and natural killer (NK) cells.
Their goodwill to bring an end tothe pandemic should be appreciated. Unfortunately, their conclusions seem premature and could lead to more damaging consequences for the public.
In theory, the drug combinationsrecommended by Unair and BIN have the potentialto inhibit SARS-CoV-2. Lopinavir and ritonavir are protease inhibitors that are currently used to treat people with HIV/AIDS. Hydroxychloroquine is a malarial treatment, while azithromycin, doxycyclineand clarithromycin are antibiotics that can fight secondary bacterial (not viral) infections in COVID-19 patients who have developed pneumonia.
However, theory does not necessarily work inpractice. Noneof these drugs have been provenin any clinical study to bea safe and effective treatmentfor COVID-19. The World Health Organization (WHO) has started clinical trials involving thousands of patients in dozens of countries to test the efficacy and safety of these drugs. So far, there has been no clear indication that these drugs, whether individually or in combination,are effective in treating COVID-19.
In fact, evidence exists that hydroxychloroquine may worsen the condition of patients, which led the WHO to suspend the clinical trial of the drug.
Unair and BIN are correct in conducting in vitro (test tube) experiments to verify the effect and toxicity of the drugs for SARS-CoV-2. Unfortunately, they have not communicated in any clear way on how they designed, executedand analyzed their experiments.
We do not know how they cultured the virus, what kind of negative controls they used, what kind of cells they testedor whether the cells they usedcontained the necessary receptors for SARS-CoV-2 to enter a human cell. More importantly, it is crucial to note thatthe results of in vitro experiments(however encouraging) cannot be assumed to be safe and effectivetreatments for direct use in human patients. For example, the United States Food and Drug Administration (FDA) on averageapprovedless than 10 percent of drugs that performed well in vitroas safe for humanprescription.
The human lungs contain millions of cells comprising dozens of different types that perform intricate interactions. The proposed drugs can also affect other organs in the human body and cause adverse reactions.
Instead of announcing that these five combination therapiesare ready for treating COVID-19, Unair and BIN should first run arandomizedcontrolled trial (RCT) to confirm their findings.Recruiting diverse patient populations is also critical to ensuring thefairness and robustness of the study.
Despite their good intentions, all the drugs that Unair and BIN researchers have proposedare strong medicines, whether individually or in combination, that can potentially cause unwanted sideeffects and even death. Surely none of us want to rush into an unproven treatmentin order to avoid developing even more overwhelming health problems in the future.
Stem cell therapy
Stem cell therapy is another COVID-19treatment that Unair and BIN researchers have proposed. Stem cells are undifferentiated cells thathas the potential to develop into many different types of cells in human body. One type of stem cell they have proposed is hematopoietic stem cells (HSCs), whichdevelop into blood cells, includingimmune cells that help the body fight pathogens and infections.
However, stem cell therapy is still considered very risky, expensiveand limited to treating a few cancers, such as leukemia. No evidence exists that stem cell therapy is efficient in treating viral infections in the human bodysuch asCOVID-19.
As with the drug therapies, the Unair and BIN researchers did not say how they performed their stem cell experiment. We have no information oncrucial aspects likestem cell culturing protocol, the stem cell's differentiation status, tumorigenic potential, proliferation capacity orexcretion patterns, and how they tested stem cell activity against SARS-CoV-2.
Even if the researchersestablished a sound experimentalprotocol for their in vitro experiments, administering stem cell therapy to COVID-19 patients is an extremely dangerous procedure that can result in undesirable costs, such as malignancy, the stem cells attacking other healthy cellsand possibly death.
Injecting stem cells into the human body carries a huge risk of immuno-rejection (think of a blood type A patient receivinga bloodtype B infusion, but witha much more severe reaction). The doctors administering the treatment must isolate autologousstem cells from the individual patient or allogenic stem cells froma separate donor, culture them, and reinject the treated cells into the patient. These processes are extremely laborious, time-consumingand expensive, and there is no clear indication that the treatment will produce a safe and successful outcome against viral infection.
This is hardly a sound strategy to use during a pandemic. Furthermore, thecommon procedureis to administer powerful immunosuppressants to reduce the strength of thepatients immune system, particularly in the allogenic scenario, which would minimizethe risk of immuno-rejection. However, it would be unwise to shut down a COVID-19patient's immune system that is neededto work properly for their body to fight SARS-CoV-2.
Unair and BIN's valiant effortsshould still be applauded, as they are committed to treating COVID-19 and ending the pandemic. The public is waiting impatiently for the health crisis to subside so they canresume their normal lives.
However, everyone should realize that discovering treatments and developing a potential vaccine for a disease that was virtually unknown six months ago takes a lot of time and resources.
Unair and BIN said that they had submitted their research to at least seven peer-reviewed internationaljournals, but this does not mean that their research is validated immediately. It still needs reviewing and questioned by their scientific peers.
It is necessary for the researchers to publish their findings onan open access, preprint repository for biological or medical research papers like BiorXiv or MedrXiv, so that scientists and people around the worldcan scrutinize and engage in healthy scientific discourse.
We absolutely deserve good news during the pandemicon safe medical treatmentsand vaccines. We also deserve complete, clear and transparent public communications from all COVID-19 stakeholders, including researchers and governments, to ensure that all actions are evidence-based, safeand effective.
The writer is a research scientist with a PhD in biochemistryfrom the University of Cambridge, which he earned as a recipient of the 2015-2019 Gates Cambridge Scholarship program.
Disclaimer: The opinions expressed in this article are those of the author and do not reflect the official stance of The Jakarta Post.
Excerpt from:
Preventing misleading claim of COVID-19 cure - The Jakarta Post - Jakarta Post
- Overcoming Tendonitis: How Stem Cell Treatments Are Revolutionizing Athlete Rehabilitation - Medical Tourism Magazine - February 21st, 2024
- Unproven Stem Cell Treatments Offer Hope & Risks - Healthline - January 4th, 2023
- Stem Cell or Bone Marrow Transplant Side Effects - American Cancer Society - November 24th, 2022
- Stem cell: $137 million buys more clinical trials, shared labs ... - November 24th, 2022
- Stem Cells Australia | Australian research, stem cell treatments and ... - October 29th, 2022
- What is a Bone Marrow Transplant (Stem Cell Transplant)? - Cancer.Net - October 29th, 2022
- Cameron Mathison Is Undergoing Stem Cell Treatments - October 4th, 2022
- Hiltzik: A judge undermines the FDA on stem cells - Los Angeles Times - October 4th, 2022
- Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD - GlobeNewswire - October 4th, 2022
- 15 Years of Heart - Newswise - October 4th, 2022
- QC Kinetix (The Heights) Helping Patients Heal Better from Joint Pain Through Houston Heights Sports Medicine - Yahoo Finance - October 4th, 2022
- Sources - Minnesota Timberwolves' Karl-Anthony Towns was on bed rest for days due to throat infection - ESPN - October 4th, 2022
- Innovative spaces and an expert team help Childrens Hospital New Orleans set the standard in cancer care - NOLA.com - September 25th, 2022
- Stem Cell Transplantation: What it Is, Process & Procedure - September 16th, 2022
- New stem cell therapy provides long-term brain protection against ALS - Study Finds - September 8th, 2022
- $150 Million Gift Takes Stem Cell Research to New Heights - University of California San Diego - September 8th, 2022
- Seattle biotech company is the first to receive approval to test B cell gene therapy in humans - GeekWire - September 8th, 2022
- Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia... - September 8th, 2022
- Could Stem-Cell Based Therapy Treat Type-1 Diabetes? A New Study Demonstrates the Treatments Potential - SciTechDaily - August 30th, 2022
- Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio - GlobeNewswire - August 30th, 2022
- Global Cancer Stem Cells Market Estimated to Reach $1,722.7 Million by 2026 and Grow at 10.3% CAGR in the 2019 to 2026 Timeframe | [180-Pages] Report... - August 22nd, 2022
- Getting a Stem Cell or Bone Marrow Transplant - American Cancer Society - August 14th, 2022
- Stem cell therapy to be used in treatment of long COVID by Panacell Biotech - Labiotech.eu - August 14th, 2022
- Selma Blair 'Stopped Looking in the Mirror' After MS Treatments - TooFab - August 14th, 2022
- ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Childrens Hospital to Develop iPSC-Derived Allogeneic... - August 5th, 2022
- Stem Cells Are Needed To Treat Life-Threatening Diseases - Longevity LIVE - Longevity LIVE - July 19th, 2022
- Stem Cell Hair Transplant: What Is It and When Will It Be Available? - July 11th, 2022
- Stem cell treatments and regulation - a quick guide for consumers - July 11th, 2022
- Tisch Multiple Sclerosis Research Center of New York Study Featured in BioSpace - Business Wire - July 3rd, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - GlobeNewswire - June 22nd, 2022
- Japan's five hottest biotech companies in healthcare - Labiotech.eu - June 22nd, 2022
- Sickle cell beta thalassemia: Causes, symptoms, and treatments - Medical News Today - June 22nd, 2022
- Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual... - June 22nd, 2022
- Six Things to Know About Stem Cell Treatment - HealthTechZone - May 15th, 2022
- CU Anschutz center for cell-based therapy gets $200 million expansion - The Denver Post - May 15th, 2022
- Differentiation therapy, Hox genes and Abemaciclib Research update 13th May - Brain Tumour Research - May 15th, 2022
- Here's the No. 1 Reason to Buy Vertex Pharmaceuticals Now - The Motley Fool - May 15th, 2022
- To help cope with the world's oldest population, Japan is investing in transplanted iPS stem cells - CBS News - April 19th, 2022
- Stem cell cure for lower back pain is all in the 'hiPS' - Study Finds - April 19th, 2022
- Versant-backed startup launches with plans to broaden cell therapy's reach - BioPharma Dive - April 19th, 2022
- CAR NK-Cell Therapy Is Quickly Growing in Immunotherapy - Targeted Oncology - April 19th, 2022
- Robert Vonderheide Appointed to Second Five-Year Term as Director of the Abramson Cancer Center - U Penn - April 19th, 2022
- Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer - DocWire News - April 19th, 2022
- Is Stem Cell Therapy Right for You? - Health Essentials from Cleveland Clinic - April 6th, 2022
- Cleveland Cord Blood Center and Deverra Therapeutics Announce Agreement - PR Newswire - April 6th, 2022
- Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says - AJMC.com Managed Markets Network - April 6th, 2022
- Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives - DocWire News - March 25th, 2022
- A Holistic Review on the Current and Future Status of Biology-Driven and Broad-Spectrum Therapeutic Options for Medulloblastoma - Cureus - March 25th, 2022
- Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL - AJMC.com Managed Markets Network - March 25th, 2022
- 'I wouldn't be here': Virginia girl, celebrating 11 years in remission, credits St. Jude with saving her life - News 3 WTKR Norfolk - March 25th, 2022
- This weird mouse with a tuft of human hair could be the future of a stem cell treatment for baldness - Boing Boing - January 20th, 2022
- 5 questions facing gene therapy in 2022 - BioPharma Dive - January 20th, 2022
- How Stem Cell and Bone Marrow Transplants Are Used to ... - January 5th, 2022
- The Stem Cell Transplant Process - UChicago Medicine - January 5th, 2022
- Next Chapters: How Northern California blood recipients are doing years after donors helped save their lives - KCRA Sacramento - January 5th, 2022
- Exclusive: Ronnie Coleman on Recent Weight Gain, Current Strength, and Health Progress - BarBend - January 5th, 2022
- Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent ... - KULR-TV - November 8th, 2021
- Managing superficial pyoderma with light therapy - DVM 360 - October 28th, 2021
- New Treatments and Tips for Dealing With Blood Cancer - Curetoday.com - October 28th, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at the - GlobeNewswire - October 16th, 2021
- Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft - MedCity News - October 16th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 16th, 2021
- FTC Follows Through On Prioritizing Investigations Into False Advertising In Healthcare Markets - Media, Telecoms, IT, Entertainment - United States -... - October 16th, 2021
- FDA Warns About Stem Cell Therapies | FDA - October 5th, 2021
- Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission - Digital Journal - October 5th, 2021
- Kite's Tecartus is First CAR T Therapy Approved for Adults with B-Cell ALL - Clinical OMICs News - October 5th, 2021
- Prolymphocytic Leukemia: What Is It and How Is It Treated? - Healthline - August 31st, 2021
- Researchers Gaze into Space to Envision Future of Regenerative Medicine - UPMC & Pitt Health Sciences News Blog - UPMC - August 18th, 2021
- Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline - August 18th, 2021
- Study Calls for COVID-19 Vaccination in Patients With Cancer to Enable Optimal Treatment Delivery During Pandemic - OncLive - August 18th, 2021
- A Third Dose of the COVID-19 Vaccine Recommended for Some Cancer Patients With Weakened Immune Systems - On Cancer - Memorial Sloan Kettering - August 18th, 2021
- Stem cells: What they are and what they do - Mayo Clinic - June 6th, 2021
- Stem Cell Therapy for Knee Pain: What Patients Should Know - June 6th, 2021
- Study clarifies the impact of getting old on hematopoietic stem cells - Microbioz India - December 26th, 2020
- Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial - Multiple Sclerosis News Today - December 22nd, 2020
- New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU - December 22nd, 2020
- Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City - PRNewswire - December 22nd, 2020
- For Patients With HMA-Resistant MDS, What Are Their Options? - AJMC.com Managed Markets Network - December 22nd, 2020
- In COVID-19 Clinical Trials, Experts from Baptist Health's Cancer Institutes Treat Patients With Mild or Severe Symptoms - Baptist Health South... - December 22nd, 2020
- SPONSORED: 12 Charities of Christmas - Anthony Nolan - The Courier - December 22nd, 2020